Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000709 · ClinicalTrials.gov registry record · Phase 3
An Open Trial of Zidovudine (AZT) Treatment of the AIDS Dementia Complex in Patients With AIDS or Low CD4+ Lymphocyte Counts
A Phase 3 study of HIV Infections and AIDS Dementia Complex, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
- 12
- Study locations
NCT00000709 is a Phase 3 study of HIV Infections and AIDS Dementia Complex that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 50 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (89% lower). The trial reports 12 study locations across 8 states.
The verdict
NCT00000709, a Phase 3 study of HIV Infections and AIDS Dementia Complex, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
- 12
- Study locations
Study Summary
To provide accurate and complete neurologic assessment of the course of the AIDS dementia complex in patients treated with zidovudine (AZT). The study will determine how frequently patients improve, how long improvement is sustained, and the magnitude and functional significance of improvement. Individuals with AIDS frequently suffer central nervous system (CNS) problems that are characterized by cognitive, motor, and behavioral deficits, in a disorder known as AIDS dementia complex. Clinical experience suggests that its course is often progressive, going from initial symptoms to moderate or severe dementia within several months. Accumulating evidence now suggests that direct brain infection by the HIV virus is the likely cause of the AIDS dementia complex. Case reports suggest that therapy with AZT, which has been shown to be a strong inhibitor of HIV replication in vitro, may alleviate the AIDS dementia complex. This study will help define the natural history of the AIDS dementia complex in treated patients.
Conditions Studied
Interventions
- DRUG Zidovudine
Study Locations (12)
Louisiana
- Charity Hosp / Tulane Univ Med School - New Orleans
- Louisiana State Univ Med Ctr / Tulane Med School - New Orleans
- Tulane Univ School of Medicine - New Orleans
New York
- Bellevue Hosp / New York Univ Med Ctr - New York
- Mem Sloan - Kettering Cancer Ctr - New York
- Univ of Rochester Medical Center - Rochester
California
- UCLA CARE Ctr - Los Angeles
Maryland
- Johns Hopkins Hosp - Baltimore
North Carolina
- Univ of North Carolina - Chapel Hill
Ohio
- Univ Hosp of Cleveland / Case Western Reserve Univ - Cleveland
South Carolina
- Julio Arroyo - West Columbia
Washington
- Univ of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Est. Completion | 1990-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000709
The ClinicalTrials.gov registry entry for NCT00000709 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (89% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Zidovudine is the first listed.
NCT00000709 reports 12 study locations spanning 8 distinct geographic areas - top geographies include Louisiana, New York, California.
Frequently Asked Questions
What is clinical trial NCT00000709 about?
NCT00000709 is a clinical study titled "An Open Trial of Zidovudine (AZT) Treatment of the AIDS Dementia Complex in Patients With AIDS or Low CD4+ Lymphocyte Counts". To provide accurate and complete neurologic assessment of the course of the AIDS dementia complex in patients treated with zidovudine (AZT). The study will determine how frequently patients improve, how long improvement is sustained, and the magnitude and functional significance of improvement. Ind...
What is the current status of trial NCT00000709?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 50 participants. Estimated completion is 1990-02.
What conditions does trial NCT00000709 study?
This clinical trial studies the following conditions: HIV Infections, AIDS Dementia Complex.
What interventions are being tested in trial NCT00000709?
The interventions under investigation include: Zidovudine (DRUG).
Who is sponsoring clinical trial NCT00000709?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000709 being conducted?
This trial has 12 study locations across California, Louisiana, Maryland, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.